The 52nd edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians. Coverage Clinical syndromes (pathogens, bacterial, fungal, mycobacterial, parasitic viral), Anti-infective agents (dosing, pediatric adjustments, renal adjustments, adverse effects, activity, pharmacology, drug-drug interactions), Preventative therapy. What's new in 2022: Numerous changes throughout, with major changes in the following New Drugs - Addition of new COVID-19 drugs, cefiderocol, ibrexafungerp, brincidofovir, cabotegravir, doravirine, and more. New Tables - ECMO Drug Dosing Adjustment (Table 10F) and QTc Prolongation (Table 10G). Table 1: Initial Choice of Antimicrobial Therapy - Numerous changes including 2021 CDC STI updates, recommendations for resistant infections. Table 5: Recommendations for MDR Bacteria -
Michael S. Saag Orden de los libros (cronológico)
Este autor es un distinguido médico e investigador, conocido principalmente por su trabajo pionero en enfermedades infecciosas, en particular el VIH. Su carrera temprana implicó descubrimientos significativos en la evolución genética del virus. Esto llevó a la conceptualización y establecimiento de una clínica ambulatoria pionera centrada en la atención integral al paciente integrada con investigación de vanguardia y ensayos clínicos. Sus extensas contribuciones incluyen más de 320 artículos revisados por pares y numerosos capítulos de libros de texto, lo que solidifica su posición como un experto líder en el campo.
The Sanford guide to antimicrobial therapy 2015
- 238 páginas
- 9 horas de lectura
The 45th edition of the leading reference on treatment of infectious diseases and anti-infective drug information. Available in print in pocket size, spiral bound and large library editions. New material and areas of significant change in this 45th edition include: * HCV treatment (Table 14G): Expanded treatment options using the newest direct acting agents (DAA) for interferon-free therapy based on the latest guidelines. * Parasitic diseases (Table 13A): Treatment of parasitic diseases has been comprehensively updated. * Antiretroviral therapy (Table 14): New once daily single tablet regimens have been added. * Antibacterial drug information (Table 9, Table 10): Pharmacology data and adverse effects summary have been extensively updated. * Resistant Bacteria (Tables 1, 5, & 6): Updates reflect the latest data and treatment options, including new agents for treatment of resistant S. aureus. -- Publisher